Citius pharmaceuticals, inc. holds pre-bla meeting with the fda for i/ontak (denileukin diftitox) for the treatment of cutaneous t-cell lymphoma

Biologics license application (bla) submission planned for the second half of 2022 cranford, n.j. , july 12, 2022 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that the company held a type b pre-bla meeting with the u.s. food and drug administration (fda) to discuss i/ontak (denileukin diftitox), an engineered il-2-diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous t-cell lymphoma (ctcl).
CTXR Ratings Summary
CTXR Quant Ranking